Edwards Lifesciences (NYSE:EW) Upgraded to Buy at TD Cowen

TD Cowen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a research report report published on Friday morning, MarketBeat Ratings reports. They currently have $97.00 target price on the medical research company’s stock, up from their previous target price of $90.00.

Several other brokerages also recently issued reports on EW. BTIG Research restated a “buy” rating and issued a $103.00 price objective (up previously from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Wells Fargo & Company set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, December 18th. Finally, Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

Edwards Lifesciences Trading Up 0.7%

Shares of NYSE:EW opened at $85.14 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock’s 50-day moving average is $85.06 and its 200-day moving average is $80.32. The company has a market cap of $49.41 billion, a P/E ratio of 36.70, a P/E/G ratio of 3.44 and a beta of 0.95. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 57,824 shares of company stock worth $4,863,323. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in the company. Level Four Advisory Services LLC boosted its position in Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after buying an additional 119 shares in the last quarter. Colonial Trust Co SC raised its stake in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after acquiring an additional 120 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after acquiring an additional 130 shares in the last quarter. Prosperity Consulting Group LLC grew its position in Edwards Lifesciences by 3.2% during the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares during the last quarter. Finally, Howard Capital Management Inc. increased its holdings in Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 132 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.